SUBSCRIBE
SUBSCRIBE
News   Drug Development

Topigen Pharmaceuticals Inc. to Advance TPI 1020 Into Phase 2 Development for COPD

September 10, 2007 | 
1 min read

MONTREAL--(MARKET WIRE)--Sep 10, 2007 -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, today announced the successful completion of a Phase 2a safety trial with TPI 1020 in smokers with asthma.

Clinical research Phase II
MORE ON THIS TOPIC
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac